化学
T7 RNA聚合酶
抄写(语言学)
信使核糖核酸
体外
细胞生物学
核糖核酸
分子生物学
聚合酶
RNA沉默
RNA依赖性RNA聚合酶
RNA聚合酶Ⅱ
RNA聚合酶
五素帽
DNA
基因表达
转录因子
生物
作者
Athul Sanjeev,Casey Hannigan,Ryan Garrity,Dhinesh Srinivasan Kamalakkannan,Victoria Clendaniel,Manini Mantri,Zach Glass,Lisa N. Kasiewicz,Jay Leipheimer,Zunera Khan,Taiji Mizoguchi,Vian Peshdary,Caroline R. Summers,Penny J. Beuning,Christopher J. Cheng
出处
期刊:
[Elsevier BV]
日期:2026-03-20
卷期号:34 (2): 201722-201722
被引量:1
标识
DOI:10.1016/j.omta.2026.201722
摘要
As mRNA emerges as a versatile tool for treating a range of diseases, efficient and scalable production remains an ongoing challenge. Inefficient co-transcriptional incorporation of cap analogs and generation of double-stranded RNA impurities are two of the major challenges that can result in increased manufacturing costs and time, as well as increased immunogenicity and reduced therapeutic potency. In an effort to overcome these challenges, we engineered T7 RNA polymerase variants to enhance capping efficiency and reduce dsRNA generation. In this work, we screened 59 T7 RNA polymerase variants and identified multiple variants, most notably R632N and Q649L, that achieved higher capping efficiency and up to 90% reduction in dsRNA impurity without compromising mRNA integrity. mRNA generated by these engineered T7 RNA polymerase variants showed enhanced translation and reduced immunogenicity in in vitro and in vivo studies. Additionally, they were observed to generate functional, relatively low-immunogenic mRNA without requiring excessive amounts of cap analogs or additional purification steps. Use of such T7 RNAP variants may thus offer a potentially cost-effective strategy for commercial scale mRNA therapeutic manufacturing.
科研通智能强力驱动
Strongly Powered by AbleSci AI